Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 1 of 1 (100%) have an AI response strategy ready
Oncimmune Limited operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data indicates 1 pending office action currently active in the system. This action is being reviewed by 1 distinct examiner, which shows a singular focus for the company's current prosecution efforts. All activity is concentrated within 1 distinct art unit, suggesting that the pending application falls within a specific technical category of biotechnology.
The busiest examiner for this portfolio is DENT, ALANA HARRIS, who is assigned 1 busiest examiner pending action. This single action accounts for the entire pending workload for the company at this time. Since there is 1 distinct examiner, the company's current experience with the USPTO is limited to the feedback and requirements of DENT, ALANA HARRIS. This creates a centralized prosecution environment where the outcome of the 1 pending office action is the primary focus for the Biotechnology & Pharmaceuticals portfolio.
Practitioners should observe that the 1:1 ratio of pending actions to distinct examiners means there is no internal comparison available for examiner behavior. The 1 distinct art unit involved indicates that the prosecution is not currently spread across different technical divisions. Consequently, the 1 busiest examiner pending action handled by DENT, ALANA HARRIS represents the total scope of the company's immediate biotechnology-related patent challenges.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005568 | USE OF ANTIGEN COMBINATION FOR DETECTING AUTOANTIBODIES IN LUNG CANCER | DENT, ALANA HARRIS | 63d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005568 | USE OF ANTIGEN COMBINATION FOR DETECTING AUTOANTIBODIES IN LUNG CANCER | DENT, ALANA HARRIS | 63d |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18005568 | USE OF ANTIGEN COMBINATION FOR DETECTING AUTOANTIBODIES IN LUNG CANCER | DENT, ALANA HARRIS | 1643 | §101§102§103§112 | Non-Final OA | 63d | AI Ready | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial